Keystone Heart today said it has acquired 510 Kardiac Devices for an undisclosed amount.
The development-stage 510 Kardiac Devices is currently developing the Lim Transseptal System to meet the demands of left-sided structural heart procedures that require a transeptal approach. The system is important in procedures such as percutaneous treatment of mitral valve disease, percutaneous occlusion of the left atrial appendage and electrophysiology procedures.
“At Keystone Heart, we are dedicated to delivering innovative products that fulfill unmet needs—like our TriGUARD 3, which is the only CE Marked cerebral embolic protection device designed to cover and protect all three cerebral vessels during transcatheter heart procedures,” president and CEO Chris Richardson said in a news release. “With the increase in left-sided structural heart procedures, Interventional Cardiologists are being asked to puncture and cross the interatrial septum using spe…